Please assess the completion status of the following clinical trial:

Trial Title: Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with relapsing remitting MS defined by 2010 revised McDonald criteria (see Appendix 4)~* Patients with Expanded Disability Status Scale (EDSS) score of 0-6.5 (see Appendix 8)~* Patients with high disease activity despite treatment with a disease modifying therapy (\> 1 relapse in the previous year, \> 9 hyperintense T2 lesions or \> 1 Gd-enhancing lesion or non-responding which could be defined as unchanged or increased relapse rate or ongoing severe relapses compared to previous year)or patients with rapidly evolving severe RRMS (e.g. \> 2 relapses with disease progression in one year and \> 1 Gd-enhancing lesion or with a significant increase in T2 lesions compared to a recent MRI)~* Depression according to ICD-10 criteria~* Mild-moderate depression assessed by BDI-II score between 14-28 inclusively measured before study inclusion and before fingolimod is administered~Exclusion Criteria:~* Patients with a history of chronic disease of the immune system other than MS which requires systemic immunosuppressive treatment, or a known immunodeficiency syndrome. Patients with Crohns disease or ulcerative colitis are excluded without exception~* History or presence of malignancy (other than localized basal or squamous cell carcinoma of the skin)~* Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS, Hepatitis B, Hepatitis C infection or to have positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests~* Negative for varicella-zoster virus IgG antibodies at Screening~* Patients who expect to be treated with any disease modifying drugs (DMD) during the study (i.e. IFN-β, glatiramer acetate); however no washout is needed for DMDs prior to start of fingolimod~* Patients who are or have been treated with:~* immunoglobulins and/or monoclonal antibodies (including natalizumab) within 3 months prior to start of fingolimod~* Systemically applied corticosteroids or adrenocorticotropic hormones (ACTH) within 1 month prior to start of fingolimod (nevertheless, topical application is permitted);~* Immunosuppressive medications such as azathioprine or methotrexate, within 3 months prior to start of fingolimod;~* Cyclophosphamid and mitoxantrone within 6 months prior to start of fingolimod~* cladribine at any time~* current psychological or pharmacological treatment for depression (MAO inhibitors in particular), a washout period of 1 month prior start of fingolimod is required~* current treatment with linezolid, a washout period of 1 month prior start of fingolimod is required~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fluoxetine and Fingolimod (Type: EXPERIMENTAL): Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Fluoxetine, supplied in blistered packs containing 20 tablets; starting dose 20 mg; final dose 40 mg
- Venlafaxine and Fingolimod (Type: EXPERIMENTAL): Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Venlafaxine, supplied in blistered packs containing 14 capsules; starting dose 75 mg; final dose 150 mg
- Citalopram and Fingolimod (Type: EXPERIMENTAL): Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Citalopram, supplied in blistered packs containing 20 tablets; starting dose 20 mg, final dose 40 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).